In last trading session, AbCellera Biologics Inc (NASDAQ:ABCL) saw 2.65 million shares changing hands with its beta currently measuring 0.50. Company’s recent per share price level of $2.35 trading at $0.12 or 5.38% at ring of the bell on the day assigns it a market valuation of $700.27M. That closing price of ABCL’s stock is at a discount of -111.91% from its 52-week high price of $4.98 and is indicating a premium of 10.21% from its 52-week low price of $2.11. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 5.18 million shares which gives us an average trading volume of 3.99 million if we extend that period to 3-months.

For AbCellera Biologics Inc (ABCL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.22. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.14 in the current quarter.

AbCellera Biologics Inc (NASDAQ:ABCL) trade information

Upright in the green during last session for gaining 5.38%, in the last five days ABCL remained trading in the red while hitting it’s week-highest on Thursday, 03/06/25 when the stock touched $2.35 price level, adding 2.49% to its value on the day. AbCellera Biologics Inc’s shares saw a change of -19.80% in year-to-date performance and have moved -1.67% in past 5-day. AbCellera Biologics Inc (NASDAQ:ABCL) showed a performance of -22.19% in past 30-days. Number of shares sold short was 19.9 million shares which calculate 4.65 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 53.0% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -112.77% in reaching the projected high whereas dropping to the targeted low would mean a loss of -112.77% for stock’s current value.

AbCellera Biologics Inc (ABCL) estimates and forecasts

This year revenue growth is estimated to fall -8.82% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 7.12M for the same. And 7 analysts are in estimates of company making revenue of 6.71M in the next quarter. Company posted 9.95M and 7.32M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -107.74% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -10.53% while estimates for its earnings growth in next 5 years are of -9.14%.

AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders

Insiders are in possession of 22.88% of company’s total shares while institution are holding 42.47 percent of that, with stock having share float percentage of 55.07%. Investors also watch the number of corporate investors in a company very closely, which is 42.47% institutions for AbCellera Biologics Inc that are currently holding shares of the company. BAKER BROS. ADVISORS LP is the top institutional holder at ABCL for having 27.53 million shares of worth $81.48 million. And as of 2024-06-30, it was holding 9.3556 of the company’s outstanding shares.

The second largest institutional holder is BAILLIE GIFFORD & CO, which was holding about 21.91 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4472 of outstanding shares, having a total worth of $64.86 million.

On the other hand, Smallcap World Fund and iShares Biotechnology ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 7.54 shares of worth $17.72 million or 2.53% of the total outstanding shares. The later fund manager was in possession of 1.45 shares on Dec 31, 2024 , making its stake of worth around $3.4 million in the company or a holder of 0.49% of company’s stock.